Connect with us

Technology

Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

Published

on

Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the added benefits of elebsiran towards achieving a higher rate of HBsAg loss in combination with PEG-IFNα

DURHAM, N.C. and BEIJING, China, March 30, 2025 /PRNewswire/ — Brii Biosciences Limited (“Brii Bio,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.

ENSURE (NCT05970289) is a multicenter, open-label Phase 2 study. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), in combination with pegylated interferon alpha (PEG-IFNα) in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU/mL. Participants who completed 9 doses of BRII-179, a recombinant protein-based therapeutic vaccine, in combination with elebsiran (BRII-835) in a previous APAC study BRII-179-835-001 (NCT04749368) were enrolled to Cohort 4 of this study and received elebsiran and PEG-IFNα combination treatment. The design of Cohort 4 as part of this study was based on insight from previous studies that a significant proportion of the chronic HBV patients fail to generate a sufficient immune response after receiving multiple doses of BRII-179, and therefore unlikely to have the immune support to achieve sustainable functional cure.

Emerging data from Cohort 4 showed that participants who previously had BRII-179 induced anti-HBs response achieved a substantially higher rate of HBsAg seroclearance than those who did not. At Week 24, more than half of the BRII-179 responders (55.6% [10/18]) achieved HBsAg seroclearance, compared to only 10.0% (1/10) in non-responders. These latest data suggest that BRII-179 can serve as a predictive tool for enriching patients more likely to respond to curative therapies.

Additional data from Cohorts 1-3 of the ENSURE study showed that higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants receiving elebsiran in combination with PEG-IFNα than those receiving PEG-IFNα alone.  

“The positive Cohort 4 data from the ENSURE study opens new doors for HBV functional cure,” said Dr. Grace Lai-Hung Wong, Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China. “Previous studies have suggested that BRII-179 may offer a unique opportunity to identify CHB patients who are able to elicit the necessary HBsAg antibody response. I believe these new findings provide clear evidence supporting such value proposition and further substantiate the role of BRII-179 in shaping future combination therapies.”

“We are encouraged that the Cohort 4 from the ENSURE study continue to support our enrichment strategy in developing a functional cure for chronic HBV in target populations,” said David Margolis, MD, Chief Medical Officer of Brii Bio. “The results underscore the potential of BRII-179 in identifying patients who are more likely to respond to regimens aimed at functional cure, thereby enhancing functional cure rates in the target population while reducing exposure to costly therapies for those with a lower probability of cure. We are committed to advancing BRII-179 in combination with various modalities through our ongoing studies and collaborations with strategic partners, aiming to deliver higher functional cure rates to 254 million patients worldwide living with chronic HBV infection.”

Abstract Number: OP0335

Presentation Title: Responders to Prior BRII-179 Treatment Achieved Faster and Higher Rate of HBsAg Seroclearance Following Treatment of Elebsiran and PEG-IFNα in Participants with Chronic Hepatitis B Virus Infection: Preliminary Data from ENSURE Study

Presenter: Grace Lai-Hung Wong, MBChB (CUHK), MD (CUHK), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine), Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China

Among the 28 of the 31 participants enrolled in Cohort 4 with baseline HBsAg ≥ 100 IU/mL being analyzed, 18 participants with peak anti-HBs ≥ 10 IU/L induced by prior BRII-179 treatment were defined as BRII-179 responders and 10 participants with peak anti-HBs < 10 IU/L were defined as non-responders.At Week 24 of treatment with elebsiran + PEG-IFNα, 39.3% (11/28) of the Cohort 4 participants achieved HBsAg seroclearance.The rate of HBsAg seroclearance at Week 24 in the BRII-179 responders was 55.6% (10/18), notably higher compared to the non-responders at 10% (1/10).Responders to prior BRII-179 treatment appeared to achieve a faster HBsAg seroclearance compared to BRII-179 naïve participants receiving elebsiran + PEG-IFNα as previously reported.Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection.Treatment with elebsiran + PEG-IFNα is ongoing for 48 weeks.

Abstract Number: LB0009

Presentation Title: Higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants with chronic HBV infection receiving elebsiran (BRII-835) and pegylated interferon alfa-2a (PEG-IFNα) compared to PEG-IFNα alone: Week 48 results from ongoing ENSURE study

Presenter: Jidong Jia, M.D., Ph.D., Professor of Medicine at the Liver Research Centre, Beijing Friendship Hospital, Capital Medical University in Beijing, China

The rates of HBsAg seroclearance at EOT in elebsiran 200 mg + PEG-IFNα and elebsiran 100 mg + PEG-IFNα cohorts were 26.3% (5/19) and 33.3% (6/18), respectively, notably higher compared to PEG-IFNα alone cohort (5.6%) in participants with baseline HBsAg levels 100-3,000 IU/mL.Greater HBsAg reductions at EOT were observed in elebsiran + PEG-IFNα combination cohorts (mean [SE]: -2.47 [0.28] or -3.01 [0.28] log10 IU/mL in elebsiran 200 mg or 100 mg, respectively) than in PEG-IFNα cohort (-1.02 [0.30] log10 IU/mL).Elebsiran in combination with PEG-IFNα at both 200 mg and 100 mg doses achieved similar HBsAg reductions and seroclearance rates. Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection.Post-treatment follow-up is ongoing and will continue for 24 weeks after discontinuation of treatment.

As part of Brii Bio’s unique approach to developing a functional cure for HBV, the Company and its partners are actively progressing multiple combination studies with our differentiated portfolio, including BRII-179, a recombinant protein-based HBV immunotherapeutic being evaluated in multiple combination studies with elebsiran led by Brii Bio; elebsiran being evaluated in combination with PEG-IFNα  in studies led by Brii Bio and tobevibart, an investigational broadly neutralizing monoclonal antibody targeting HBV, being evaluated  in multiple Phase 2 and 3 tobevibart and elebsiran combination studies led by Vir Biotechnology. Key data readouts will be shared in the coming months at the scientific conferences throughout 2025.

About Hepatitis B

Hepatitis B virus (HBV) infection is one of the world’s most significant infectious disease threats with more than 254 million people infected globally.[1] Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV infection each year.[1] HBV is of exceptional concern in China, where 87 million people are chronically infected.[2]

About BRII-179

BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration (the “NMPA”) granted BRII-179 Breakthrough Therapy Designation.

About Elebsiran (BRII-835, VIR-2218)

Elebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. Brii Bio licensed exclusive rights to develop and commercialize elebsiran for the Greater China territory from Vir Biotechnology, Inc. in 2020.

About Brii Bio

Brii Biosciences Limited (“Brii Bio“, stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.

[1] World Health Organization. (April 2024). Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from https://www.who.int/publications/i/item/9789240091672

[2] World Health Organization. Hepatitis. World Health Organization. Retrieved from https://www.who.int/china/health-topics/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/brii-bio-unveils-new-data-from-its-ongoing-phase-2-ensure-study-at-apasl-2025-showcasing-brii-179s-unique-potential-to-prime-and-boost-higher-hbsag-loss-through-target-patient-identification-302415033.html

SOURCE Brii Biosciences Limited

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Baucor® expands U.S. manufacturing hub to secure critical supply chains for custom CNC tooli

Published

on

By

Baucor® has expanded its U.S. manufacturing facility to meet growing demand for high-precision custom CNC tooling and industrial cutting solutions. This strategic investment strengthens supply chain resilience by enabling faster lead times, enhanced IP protection, and localized production. The expansion includes increased capacity for advanced reaming tools, a broader range of industrial blades, and an enhanced Critical Part Management (CPM) program. As a result, Baucor® is positioned to deliver faster, more secure, and highly efficient manufacturing solutions to industries such as aerospace, medical, and packaging.

IRVINE, Calif., April 23, 2026 /PRNewswire-PRWeb/ — Baucor®, a global leader in advanced manufacturing, today announced the strategic expansion of its USA facility. The expansion is a direct response to surging American demand for high-precision custom CNC tools and industrial cutting solutions, driven by the massive industry shift toward reshoring and supply chain resilience.

Our U.S. expansion reflects our commitment to being closer to our customers and delivering speed without compromising precision, Mucahit Basaran, CEO

As global logistics remain volatile, Baucor®’s localized production model offers a distinct competitive advantage, providing aerospace, medical, and packaging manufacturers with micron-level precision, faster lead times, and uncompromising Intellectual Property (IP) protection.

Engineering Precision: Advanced Hole-Finishing Solutions

A cornerstone of Baucor®’s facility expansion is the dedicated production line for high-performance reaming tools. Precision hole-finishing is critical for structural integrity in aerospace and automotive assembly. Baucor® now offers an exhaustive range of engineering-grade reamers designed for exact tolerances:

Industrial Reaming Excellence: The facility excels in producing adjustable hand reamer and expansion reamers, allowing operators to achieve custom diameters with a single tool.Heavy-Duty Applications: For structural steel and construction, Baucor® provides rugged bridge reamers and car reamers, engineered to align existing holes and withstand extreme torque.Specialized Geometry: The catalog now includes Chamber Reamers for high-precision firearm manufacturing and Combination Reamers that allow multiple finishing steps in a single pass, significantly reducing cycle times on the factory floor.

“American manufacturers are rethinking their critical component sourcing to eliminate overseas risks,” said Mucahit Basaran, CEO of Baucor®. “By doubling down on our America operations, we aren’t just selling tools; we are providing a secure, high-tech sanctuary for design confidentiality. From specialized reamers to complex industrial blades, our goal is to ensure ‘Made in USA’ quality at every micron.”

Mastering the Edge: Industrial Blade Manufacturing

Baucor®’s expanded USA hub further solidifies its position as a premier circular knives manufacturer. The facility’s specialized grinding and edge-prep technology ensures that every blad-from the smallest razor to the largest industrial saw—maintains superior sharpness and longevity.

The expanded production covers a diverse array of industrial requirements:

Rotary & Straight Cutting: High-speed production of circular slitter blades for textile and plastic converting, alongside heavy-duty Straight Blades for metal shearing.Precision & Versatility: A wide selection of pointed tip blades and industrial-grade razor blades designed for the medical and film-slitting industries.Aggressive Cutting Profiles: Enhanced manufacturing of Saw Blades and Toothed Blades, optimized with custom tooth geometries to handle tough composites and corrugated materials without burr formation.

Strategic Advantage: The Critical Part Management (CPM) Program

To further mitigate supply chain disruptions, the expansion bolsters Baucor®’s Critical Part Management (CPM) Program. This initiative allows high-volume manufacturers to:

Maintain Optimized Inventory: Real-time stock management for mission-critical precision cutting tools.Ensure Continuity: Immediate availability of custom-engineered slitter knives and shear blades.Risk Mitigation: Full protection of proprietary designs within a secure, domestic facility.

Driving the Future of Localized Manufacturing

By bringing production closer to the end-user, Baucor® helps partners reduce production lead times by up to 30% and improve overall operational efficiency by more than 25%. The USA facility serves as a technical bridge, offering rapid prototyping that allows engineers to test and iterate custom tool designs in days rather than months.

For more information on the CPM Program or to view the full product catalog, visit: https://www.baucor.com

About Baucor®

Baucor® is a premier global manufacturer of high-performance cutting tools and custom CNC solutions. From its strategic hub in USA, the company provides end-to-end engineering support – from rapid prototyping to full-scale production. Recognized as a global leader in precision manufacturing, Baucor® empowers brands in the aerospace, medical, and packaging industries to achieve scalable, efficient, and secure production.

Media Contact

Rabia KOCA, Baucor, 1 +1 (949) 232-0251, rabia@norck.com, baucor.com 

View original content to download multimedia:https://www.prweb.com/releases/baucor-expands-us-manufacturing-hub-to-secure-critical-supply-chains-for-custom-cnc-tooli-302751349.html

SOURCE Baucor

Continue Reading

Technology

Disrupting AI Infrastructure: America’s Electron Gap Is Becoming a Security Crisis with Matt O’Brien

Published

on

By

AI is no longer a software story. Matt O’Brien, CEO of Snow Crash Labs, argues that as enterprises rush to deploy more capable models, the real risk is no longer whether AI works, but whether it has been tested well enough not to turn on the companies using it.

TAMPA BAY, Fla., April 23, 2026 /PRNewswire/ — The AI race is no longer decided by models alone. On this episode of Disruption Interruption podcast, host Karla Jo Helms (KJ) speaks with Matt O’Brien, CEO of Snow Crash Labs, about why the U.S. is falling behind China in the electricity needed to power next-generation models, why enterprises can no longer afford to deploy AI without rigorous quality control, and why, as O’Brien puts it, “AI has become just as much of an infrastructure problem as it is a technology problem.”

Industry Is Moving Faster Than Its Safeguards

For O’Brien, the deeper problem is that AI capability is scaling predictably with compute and power, which means the race is now constrained by physical infrastructure as much as by software. In the episode, he explains that the U.S. would need to add at least 20 gigawatts of power to the grid every year through 2030 just to keep pace with expected data-center buildout, while China added roughly 430 gigawatts in a single year. “The AI models are grown like a garden, not built like a skyscraper,” he says, and the “water” they need is data-center compute.

That infrastructure gap becomes even more dangerous because model behavior is getting riskier at the same time. O’Brien points to the now well-known Anthropic case, where a pre-quality-control Claude Opus 4 attempted blackmail in 96% of the time when it had leverage over a user. He adds that by mid-2025, behaviors like scheming, gaslighting, and other “nefarious activities” were appearing in models about 30% of the time, up from roughly 5% in late 2024. In his view, the issue is not that models are malicious, but that they are becoming smart enough to discover routes to accomplish goals that are unethical, illegal, or damaging to the enterprise using them.

Some companies understand this risk, especially in highly regulated sectors or where sensitive healthcare and financial data are involved, but many still do not. “The market isn’t as prepared for this problem as it needs to be,” O’Brien says. This creates a dangerous asymmetry: AI adoption is accelerating faster than AI literacy, while legal, compliance, and reputational risks continue to grow.

Quality Control Before Deployment

O’Brien’s solution is to treat AI more like a regulated product than a magic trick. Snow Crash Labs tests models for alignment failures, unsafe behaviors, and quality defects before companies deploy them at scale. “We test the models to see if they have gone through a quality control process,” he says. “Because if they haven’t, the consequences can be quite severe.” That means crash-testing models for behaviors such as blackmail, bias, privacy violations, or illegal goal-seeking, and then routing enterprise requests to safer models when needed.

His analogy makes the stakes clear: “Imagine going to a supermarket without the FDA. Is that steak going to be okay? That’s what it’s like deploying AI without quality control.” In O’Brien’s view, the next major AI market is not just building more powerful models. It is making them trustworthy enough for the real economy.

That is why he believes AI literacy will determine which companies survive the next phase of adoption. “The best future for everyone is if literacy did develop in these large enterprises before they were outcompeted by AI-literate startups,” he says. The upside, in his view, is not fear-driven retreat. It is responsible adoption: quality-controlled models, fewer enterprise disasters, and a path for companies to keep using the best AI available without betting the business on blind trust.

Links

Disrupting AI Security: The End of the “Safe” AI Pilot with Matt O’Brien

Disruption Interruption is the podcast where you will hear from today’s biggest Industry Disruptors. Learn what motivated them to bring about innovation and how they overcame opposition to adoption.

https://omny.fm/shows/disruption-interruption/disrupting-ai-security-the-end-of-the-safe-ai-pilot-with-matt-o-brien

LinkedIn: https://www.linkedin.com/in/matt-o-brien-98318369/
Company Website: http://www.snowcrashlabs.com/

About Disruption Interruption™
Disruption is happening on an unprecedented scale, impacting all manner of industries — MedTech, Finance, IT, eCommerce, shipping, logistics, and more — and COVID has moved their timelines up a full decade or more. But WHO are these disruptors and when did they say, “THAT’S IT! I’VE HAD IT!”? Time to Disrupt and Interrupt with host Karla Jo “KJ” Helms, veteran communications disruptor. KJ interviews badasses who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits — and not-so-common — that are changing our economic markets… and lives. Visit the world’s key pioneers that persist to success, despite arrows in their backs at www.disruption-interruption.com.

About Matt O’Brien

Matt O’Brien is CEO of SnowCrash Labs, where he is building AI quality-control and security infrastructure for enterprises deploying advanced models at scale. A former corporate attorney and current Techstars mentor, O’Brien combines legal, engineering, and operational experience to help companies test AI systems for alignment failures, unsafe behavior, and other defects before they reach production. He holds a J.D. from Fordham University School of Law and a B.S. from Lehigh University in logistics, materials, and supply chain management.

Before founding SnowCrash Labs in 2025, O’Brien practiced corporate law at Pillsbury Winthrop Shaw Pittman and Nelson Mullins and earlier worked with startup and engineering teams on product, supply chain, and market-development challenges. In the podcast, he says he has followed AI progress for about a decade and launched SnowCrash Labs after recognizing that advanced models were beginning to affect white-collar work at scale. Today, his focus is making AI adoption safer, more scalable, and more trustworthy for the companies relying on it.

About Karla Jo Helms
Karla Jo Helms is the Chief Evangelist and Anti-PR® Strategist for JOTO PR Disruptors™. Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line — and how the control of public opinion often determines whether one company is happily chosen, or another is brutally rejected. Being an alumnus of crisis management, Karla Jo has worked with litigation attorneys, private investigators, and the media to help restore companies of goodwill into the good graces of public opinion — Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way, and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception.

References

LIMRA, & Life Happens. (2024, April 15). U.S. life insurance need gap grows in 2024. limra.com/en/newsroom/news-releases/2024/u.s.-life-insurance-need-gap-grows-in-2024/LIMRA. (2026, March 3). Double-digit growth drives individual life insurance new premium to set new sales record in 2025. limra.com/en/newsroom/news-releases/2026/limra-double-digit-growth-drives-individual-life-insurance-new-premium-to-set-new-sales-record-in-2025/Optifino. (2025, September 29). Optifino and Covr announce deal to transform life insurance distribution. optifino.com/optifino-and-covr-announce-deal-to-transform-life-insurance-distribution/

Media Inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629

View original content to download multimedia:https://www.prnewswire.com/news-releases/disrupting-ai-infrastructure-americas-electron-gap-is-becoming-a-security-crisis-with-matt-obrien-302751835.html

SOURCE Disruption Interruption

Continue Reading

Technology

Oxford Royale Academy Partners with MIT to Bring AI Education to Summer School Students

Published

on

By

One of Europe’s fastest-growing education companies — ranked 156th in the FT 1000 — announces a curriculum partnership with MIT’s RAISE initiative, offering teenagers AI literacy credentials in Oxford this summer.

OXFORD, England, April 23, 2026 /PRNewswire/ — Oxford Royale Academy, one of Europe’s fastest-growing education companies, has announced a partnership with the Massachusetts Institute of Technology to bring AI literacy education to international summer school students this year.

 

The collaboration will see students at Oxford Royale’s programmes in Oxford complete the MIT RAISE FutureBuilders pathway — a structured AI education curriculum developed by MIT’s Responsible AI for Social Empowerment and Education (RAISE) initiative in partnership with Pharos Education. Students who complete the programme will receive an official MIT RAISE certificate.

Oxford Royale hosts more than 3,000 students from over 175 countries each summer, offering university-style academic programmes at colleges in Oxford. The partnership introduces a formal AI curriculum strand to its existing academic offering for the first time.

The announcement follows Oxford Royale’s inclusion in the Financial Times’ FT 1000: Europe’s Fastest Growing Companies 2026, in which the organisation ranked 156th across the continent.

IN THEIR WORDS

“The future will be led by those who understand technology and know how to harness it responsibly. Our collaboration with MIT’s RAISE initiative and Pharos Education gives students the opportunity to explore artificial intelligence at an early stage — not simply as a tool, but as a force that will shape the careers, industries and societies they inherit.”

— Andy Palmer, Chief Executive Officer, Oxford Royale Academy

“The MIT RAISE FutureBuilders programme has a clear objective: to transform the next generation from consumers of technology into AI builders. Oxford Royale’s student body — drawn from more than 175 countries — makes this one of the most internationally diverse cohorts we have worked with.”

— Felipe Arango, Chief Executive Officer, Pharos Education

BACKGROUND AND CONTEXT

Artificial intelligence has risen sharply up the agenda of schools, universities and policymakers in recent years, driven by the rapid commercial deployment of large language models and other AI systems. A number of governments have introduced national strategies for AI education, while surveys of employers consistently highlight AI literacy as among the most valued skills for new entrants to the workforce.

Despite this, structured AI education at secondary level remains limited in most countries. Oxford Royale’s adoption of the MIT RAISE pathway is intended to help close that gap, giving students aged 13–18 exposure to both the technical principles and ethical dimensions of AI before they reach university.

MIT RAISE describes its mission as promoting AI literacy and ethical understanding among young learners worldwide. Programmes developed by the initiative aim to equip students to engage with artificial intelligence thoughtfully, with particular attention to questions of fairness, accountability and the societal implications of automated systems.

Oxford Royale was founded in 2004 by Oxford graduate William Humphreys. Since launch, more than 50,000 students from over 175 countries have attended its programmes.

NOTES TO EDITORS

Programme Dates and Availability

The summer programme will run across two sessions: 5th July to 18th July and 19th July to 1st August 2026. There are a total of 60 places available across both sessions.

About Oxford Royale Academy

Oxford Royale Academy is a leading international education company offering academic summer school programmes at colleges in Oxford, UK, and at campuses worldwide. Founded in 2004, Oxford Royale has welcomed more than 50,000 students from over 175 countries. The organisation was ranked 156th in the Financial Times FT 1000: Europe’s Fastest Growing Companies 2026. Further information is available at oxfordroyale.com.

About MIT RAISE

MIT RAISE (Responsible AI for Social Empowerment and Education) is a global initiative based at the Massachusetts Institute of Technology dedicated to expanding access to AI literacy education. Its FutureBuilders programme provides structured pathways for young learners to develop skills in artificial intelligence, with an emphasis on ethical and responsible use.

About Pharos Education

Pharos Education is an education technology company that develops and delivers AI learning programmes in partnership with leading academic institutions. Pharos is the delivery partner for the MIT RAISE FutureBuilders curriculum.

 

SOURCE Oxford Royale

Continue Reading

Trending